Back to Startups

CrossBridgeBio

About CrossBridgeBio

Developing a dual payload platform for non-GLP NHP toxicity data.

Business Information
Target Customers
biopharmaceutical companies research institutions contract research organizations
Industry Categories
Bioscience & Disease Healthcare Systems Deep Tech
Business Model
Revenue Model B2B services
Pricing Strategy Custom pricing based on project scope
Sales Channels direct sales, partnerships with research institutions
Funding Timeline
Round Date Amount Investors
Series A May 17, 2025 Undisclosed Unknown
Founders

No founder information available.

Investors

No investor information available.

Recent Mentions
Mykalt45
Michael Torres @Mykalt45
May 17, 2025

Board meeting on Monday. Series A coming into focus for @CrossBridgeBio. Data set we promised with our seed raise is finishing: Non-GLP NHP tox with our EGCit dual payload platform. We’re very encouraged by what we’re seeing! We were invited to speak at World ADC. Exciting!